Antibodies Directed Against Programmed Death-1 (PD-1)

Abstract

The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.

What is claimed is: 
     
         1 . A method of treating a disorder in a human that is responsive to PD-1 inhibition, the method comprising administering to the human an effective amount of an antibody comprising: a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and a light chain polypeptide comprising the amino acid sequence of SEQ ID NO: 2, whereupon the disorder is treated in the human. 
     
     
         2 . The method of  claim 1 , wherein the disorder is cancer. 
     
     
         3 . The method of  claim 2 , wherein the cancer is: adenocarcinoma, endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, stomach cancer, small intestine cancer, squamous cell carcinoma of the anogenital region, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, stomach cancer, bladder cancer, gall bladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, squamous cell carcinoma of the head and neck, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, and a hematological cancer, such as multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma/primary mediastinal B-cell lymphoma, or chronic myelogenous leukemia. 
     
     
         4 . The method of  claim 2 , wherein the cancer: is characterized by microsatellite instability, is microsatellite instability high (MSI-H), has high tumor mutational burden (TMB), has a defective DNA mismatch repair system, has a defect in a DNA mismatch repair gene, is a hypermutated cancer, or comprises a mutation in polymerase epsilon (POLE).